User login
Key clinical point: Routine clinical management of migraine using erenumab in occupationally active patients reduces the number of sick leave days and healthcare visits.
Main finding: Compared with the 12-month period before treatment initiation, a significant reduction in the number of headache-related sick leave days (4.9 vs. 1.3 sick leave days per patient-year; P = .035) and headache-related healthcare visits (4.9 vs. 2.7 visits per patient-year; P < .001) was observed over 12 months after treatment initiation.
Study details: This real-world retrospective registry analysis included 82 occupationally active patients with migraine who had 2 or more unique erenumab prescriptions and did not switch to an alternative calcitonin gene-related peptide inhibitor.
Disclosures: The study was supported by Novartis Finland Oy, Espoo, Finland. A few of the authors, including the lead author, declared serving as employees of Novartis Finland Oy while conducting the study. Amgen and Novartis have co-developed erenumab.
Source: Autio H et al. Neurol Ther. 2021 Dec 10. doi: 10.1007/s40120-021-00303-x.
Key clinical point: Routine clinical management of migraine using erenumab in occupationally active patients reduces the number of sick leave days and healthcare visits.
Main finding: Compared with the 12-month period before treatment initiation, a significant reduction in the number of headache-related sick leave days (4.9 vs. 1.3 sick leave days per patient-year; P = .035) and headache-related healthcare visits (4.9 vs. 2.7 visits per patient-year; P < .001) was observed over 12 months after treatment initiation.
Study details: This real-world retrospective registry analysis included 82 occupationally active patients with migraine who had 2 or more unique erenumab prescriptions and did not switch to an alternative calcitonin gene-related peptide inhibitor.
Disclosures: The study was supported by Novartis Finland Oy, Espoo, Finland. A few of the authors, including the lead author, declared serving as employees of Novartis Finland Oy while conducting the study. Amgen and Novartis have co-developed erenumab.
Source: Autio H et al. Neurol Ther. 2021 Dec 10. doi: 10.1007/s40120-021-00303-x.
Key clinical point: Routine clinical management of migraine using erenumab in occupationally active patients reduces the number of sick leave days and healthcare visits.
Main finding: Compared with the 12-month period before treatment initiation, a significant reduction in the number of headache-related sick leave days (4.9 vs. 1.3 sick leave days per patient-year; P = .035) and headache-related healthcare visits (4.9 vs. 2.7 visits per patient-year; P < .001) was observed over 12 months after treatment initiation.
Study details: This real-world retrospective registry analysis included 82 occupationally active patients with migraine who had 2 or more unique erenumab prescriptions and did not switch to an alternative calcitonin gene-related peptide inhibitor.
Disclosures: The study was supported by Novartis Finland Oy, Espoo, Finland. A few of the authors, including the lead author, declared serving as employees of Novartis Finland Oy while conducting the study. Amgen and Novartis have co-developed erenumab.
Source: Autio H et al. Neurol Ther. 2021 Dec 10. doi: 10.1007/s40120-021-00303-x.